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Introduction {#sec005}
============

According to recent EASL HCC guidelines, approximately 854,000 new cases of liver cancer are diagnosed annually, among which hepatocellular carcinoma (HCC) is the most frequent type, accounting for up to 90 percent \[[@pone.0223514.ref001]\]. It is also the fifth most common cancer and the third most common cause of cancer-related death globally \[[@pone.0223514.ref002], [@pone.0223514.ref003]\]. The evolution of HCC is a multistep process from chronic liver disease to liver cirrhosis to primary HCC and eventually to metastatic HCC \[[@pone.0223514.ref004]\]. Patients who are diagnosed with HCC at an inchoate stage are more likely to be cured and have a 70% chance of living more than 5 years with the appropriate therapies such as hepatectomy or liver transplantation. Those who are diagnosed at an advanced stage, in contrast, qualify only for palliative treatments and have unsatisfactory median survival times ranging from 1 to 2 years \[[@pone.0223514.ref005]\]. These data corroborate the importance of early and accurate HCC diagnosis.

Some guidelines have ruled out α-fetoprotein (AFP) and recommend ultrasound (US) as the standard HCC monitoring procedure in cirrhotic patients \[[@pone.0223514.ref006], [@pone.0223514.ref007]\]. A recent meta-analysis concluded that US plus AFP may serve as an updated screening strategy for early HCC. However, the sensitivity and specificity are still low (63% and 45%, respectively) \[[@pone.0223514.ref005]\]. Moreover, many non-invasive screening tools, such as non-coding RNAs, des-γ-carboxyprothrombin and midkine (MK), have been investigated for use in the diagnosis of HCC \[[@pone.0223514.ref008]\]. As early as 1996, the serum level of MK assessed by enzyme-linked immunoassay (EIA) was found to be undetectable or lower than 0.6 ng/mL in healthy participants. However, more than fifty percent of HCC patients have an MK value varying from 0.6 to 8 ng/mL \[[@pone.0223514.ref009]\]. Using EIA, Ikematsu *et al* found that the highest level of normal serum MK does not reach 0.5 ng/mL, whereas the serum MK levels in 25 HCC cases were all greater than 0.5 ng/mL \[[@pone.0223514.ref010]\]. In addition, the secretory characteristic of MK makes it easy to quantitate in blood samples. All these characteristics indicate that MK has a promising future as a tool for non-invasive, early and sensitive HCC diagnosis \[[@pone.0223514.ref011]\]. However, the small number of cases in each study has limited the accuracy of the results, and the diagnostic ability of MK has not yet been fully elucidated. We conducted a systematic review and meta-analysis to determine the diagnostic power of MK for HCC.

Methods {#sec006}
=======

Drafted based on a preset protocol registered with PROSPERO 2018 (<https://www.crd.york.ac.uk/PROSPERO/>, CRD42018103537), the current meta-analysis was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement ([S1 Table](#pone.0223514.s002){ref-type="supplementary-material"}) \[[@pone.0223514.ref012]\].

Eligibility criteria {#sec007}
--------------------

We enrolled studies that evaluated the use of the blood level of MK for the diagnosis of HCC. Studies with insufficient data or those including subjects with other types of liver tumours were excluded. If two studies had an identical cohort, we excluded the less informative one or the one with a smaller population.

Identification and selection of studies {#sec008}
---------------------------------------

We systematically searched electronic databases including PubMed, EMBASE, Web of Science and China Biology Medicine disc (CBMdisc) from the data of database inception to January 2019, without imposing language restrictions. We used the MeSH terms "liver", "neoplasms", "carcinoma", "midkine", "sensitivity and specificity", "roc curve" and "diagnosis" for literature retrieval. Details of the search strategies for PubMed and EMBASE are presented in [S1 Fig](#pone.0223514.s001){ref-type="supplementary-material"}. For CBMdisc, the combination of Chinese and English was required. Relevant unpublished work concerning MK and HCC was detected through a grey literature search of meeting proceedings and abstracts from the American Association for Cancer Research and American Society of Clinical Oncology. Finally, we identified candidate articles from the references of pertinent reviews and original studies.

First, the titles and abstracts of retrieved studies were independently screened and filtered by two investigators (B-H.Z. and B.L.). Second, the eligibility of the full-text articles was determined through separate scrutinization by two investigators. Duplicate use of an identical cohort was carefully evaluated. Disagreements were resolved through discussion or consultation with the third investigator (J-Y.Y.).

Data extraction and quality assessment {#sec009}
--------------------------------------

Two investigators (B-H.Z. and B.L.) independently extracted information the below. First, the following main characteristics of the included studies were extracted: first author name, year of publication, country, sample type, number of participants, age, sex distribution, type of controls, detection method and cutoff values. Second, the following data concerning the diagnostic accuracy were collected: true positive (TP) rate, false positive (FP) rate, false negative (FN) rate, true negative (TN) rate, sensitivity and specificity. All data are publicly available in Open Science Framework (osf.io/gw8em/). The generic Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool for diagnostic accuracy studies was applied for the quality evaluation of the enrolled studies \[[@pone.0223514.ref013]\]. Two investigators (B-H.Z. and B.L.) independently rated the four domains for the "Risk of Bias" and "Applicability Concerns". Consensus was reached through deliberation.

Data synthesis {#sec010}
--------------

We fitted hierarchical models when there were at least 4 studies available. All calculations were accomplished with the package 'mada' in R (version 3.6.0). Cells in the contingency table that were zero needed a continuous correction with a recommended value of 0.5 for data analyses because certain ratios did not exist.

The sensitivity and specificity with corresponding 95% CIs were recalculated from the TP, FP, FN and TN rates extracted via a 2 × 2 table from each included study. The threshold effect was initially determined by the correlation between the sensitivity and false positive rate (1---specificity) through the visual evaluation of coupled forest plots and was further verified by the Spearman correlation coefficient ρ (\> 0.6) between the logit of sensitivity and the logit of the false positive rate \[[@pone.0223514.ref014]\].

The bivariate random effects model by Reitsma *et al*. \[[@pone.0223514.ref015]\] for diagnostic meta-analyses was applied to obtain the pooled estimates of the sensitivity, specificity, positive likelihood ratio (LR+) and negative likelihood ratio (LR−). Additionally, the hierarchical summary receiver operating characteristic (HSROC) curves were calculated with both the Rutter & Gatsonis and Rücker & Schumacher approaches \[[@pone.0223514.ref016], [@pone.0223514.ref017]\]. We implemented independent evaluations of the diagnostic performance based on the diagnostic odds ratio (DOR) using the DerSimonian and Laird (DSL) model \[[@pone.0223514.ref018]\] and the area under the curve (AUC) using Holling's model \[[@pone.0223514.ref019]\]. The heterogeneity of the DOR was determined using the chi-squared test and Higgins' inconsistency index (I^2^). The statistic for the chi-squared test was Q, and a corresponding p value was calculated for the qualitative assessment of heterogeneity. We set 0.1 as the cutoff significance level \[[@pone.0223514.ref020]\]; however, with only 9 studies included in our investigation (\< 20), the Q test should be interpreted very cautiously \[[@pone.0223514.ref021]\]. Higgins's I^2^ statistic, calculated via the formula *I*^*2*^ = 100% × (*Q*---*df*)/*Q*, was also calculated as a measure of between-study heterogeneity \[[@pone.0223514.ref022]\]. The level of heterogeneity was deemed negligible, moderate, and considerable for I^2^ values of 25%, 50%, and 75%, respectively \[[@pone.0223514.ref022]\]. We also conducted a series of prespecified subgroup analyses based on sample type, number of participants, country, control type and cutoff values. Two different thresholds (≤0.5 ng/mL and \>0.5 ng/mL) were chosen for the exploration of diagnostic accuracy in reference to the existing practice \[[@pone.0223514.ref010]\]. Deeks' funnel plot was generated to test for publication bias \[[@pone.0223514.ref023]\].

Results {#sec011}
=======

Study selection and characteristics {#sec012}
-----------------------------------

As seen in the flowchart, a total of 139 articles met the preliminary standards, including 41 from PubMed, 42 from EMBASE, 28 from Web of Science and 28 from CBMdisc ([Fig 1](#pone.0223514.g001){ref-type="fig"}). Ninety-three records remained after removing duplicates. Additionally, 55 irrelevant studies and 10 reviews and meta-analyses were excluded based on screening the titles and abstracts. The remaining 28 articles were considered eligible for full-text review. Nineteen additional studies comprising 16 with insufficient data, 2 with identical cohorts and 1 with a case group composed of patients with cholangiocarcinoma were excluded. A manual search for grey literature and references found no applicable results. These strict eliminations yielded a group of 9 articles (11 studies) for inclusion in the meta-analysis \[[@pone.0223514.ref024]--[@pone.0223514.ref032]\], one of which was a poster presentation \[[@pone.0223514.ref024]\]. The studies were conducted in China, Egypt, Taiwan and Australia.

![Flow diagram of the literature search process and study inclusion.](pone.0223514.g001){#pone.0223514.g001}

The primary attributes of the enrolled studied were summarized and are listed alphabetically in [Table 1](#pone.0223514.t001){ref-type="table"} and [S2 Table](#pone.0223514.s003){ref-type="supplementary-material"}. Six studies also analysed the diagnostic potential of AFP \[[@pone.0223514.ref024], [@pone.0223514.ref025], [@pone.0223514.ref028], [@pone.0223514.ref030]--[@pone.0223514.ref032]\], and only three studies addressed the combined diagnostic potential of AFP and MK \[[@pone.0223514.ref028]--[@pone.0223514.ref030]\]. Due to the scarcity of studies, we did not calculate the indexes relating to the combined AFP and MK group. The number of participants in each study ranged from 70--833, with a median of 164. In total, the meta-analysis included 1941 individuals, namely, 834 HCC patients and 1107 non-HCC participants. Specifically, the non-HCC participants included 123 with gastrointestinal tumour (GIT), 73 with benign liver tumour (BLT), 453 with liver cirrhosis, 27 with chronic hepatitis C (CHC), 86 with chronic hepatitis B (CHB), 50 with benign gastrointestinal disease (BGID) and 295 healthy people. Enzyme-linked immunosorbent assay (ELISA) served as the uniform testing method \[[@pone.0223514.ref024]--[@pone.0223514.ref028], [@pone.0223514.ref030]--[@pone.0223514.ref032]\] for serum MK. Only one study investigated the MK level in whole blood, and they performed the experiment with TaqMan \[[@pone.0223514.ref029]\].

10.1371/journal.pone.0223514.t001

###### Characteristics of included studies.

![](pone.0223514.t001){#pone.0223514.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author               Year   Country     Sample   Case (HCC)   Control              Method   Cut-off\                                                                              
                                                                                              (ng/mL)                                                                               
  -------------------- ------ ----------- -------- ------------ -------------------- -------- ---------- ------------ -------- ------------------------------------------- -------- -------
  Habachi *et al*      2018   Egypt       Serum    86           \-                   \-       89         \-           \-       89 Cirrhosis                                ELISA    5.1

  Hodeib *et al*       2017   Egypt       Serum    35           49.10±4.60           9/26     35         48.00±4.40   11/24    35 Normal                                   ELISA    0.65

  Hung *et al*         2011   Taiwan      Serum    72           \-                   \-       120        \-           \-       54 GIT, 6 BLT, 10 Cirrhosis, 50 BGID        ELISA    0.5

  Li *et al*           2006   China       Serum    104          \-                   \-       60         \-           \-       20 BLT, 20 Cirrhosis, 20 Normal             ELISA    0.07

  Mashaly *et al*      2018   Egypt       Serum    44           58.11±1.05           11/33    31         56.55±1.37   13/18    31 Cirrhosis                                ELISA    1.683

  Saad *et al*         2013   Egypt       Blood    29           55.60±7.90           9/20     45         \-           14/31    18 Cirrhosis, 27 CHC                        TaqMan   \-

  Shaheen *et al*      2015   Egypt       Serum    40           52                   10/30    30         48           12/18    30 Cirrhosis                                ELISA    0.387

                                          Serum    40           52                   10/30    30         45           13/17    30 Normal                                   ELISA    \-

  Vongsuvanh *et al*   2016   Australia   Serum    86           62.20±11.40          11/75    172        \-           22/150   86 Cirrhosis, 86 CHB                        ELISA    0.44

  Zhu *et al*          2013   China       Serum    252          \<50(99), ≥50(153)   33/219   455        \-           \-       69 GIT, 47 BLT, 129 Cirrhosis, 210 Normal   ELISA    0.654

                                          Serum    86           \<50(35), ≥50(51)    18/68    40         \-           \-       40 Cirrhosis                                ELISA    0.654
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: HCC hepatocellular carcinoma, F/M female versus male, ELISA enzyme-linked immunosorbent assay, GIT gastrointestinal tumor, BLT benign liver tumor, BGID benign gastrointestinal disease, CHC chronic hepatitis C, CHB chronic hepatitis B, SD standard deviation.

\*Numbers were presented as mean±SD, median or range.

Quality assessment {#sec013}
------------------

The results of the QUADAS-2 assessment regarding the risk of bias and applicability concerns are summarized in [S3 Table](#pone.0223514.s004){ref-type="supplementary-material"}. We did not assign quality scores because of underlying heterogeneity \[[@pone.0223514.ref033]\].

The details are presented below: for the "risk of bias", the major concerns were "patient selection" and the "index test". This was mainly due to the uncertainty of whether consecutive or random sample collection was used, the case-control design, the arbitrary use and absence of a preset cutoff value. In the absence of explicit reference standards, two studies were marked as high risk. In addition, studies without the presentation of an appropriate interval between the index test and the reference standard were deemed unclear or risky. With regard to the "applicability concerns", most of the included studies showed low risk, and the two unclear risk studies did not describe the reference standard; hence, we could not evaluate the applicability.

Diagnostic accuracy {#sec014}
-------------------

In general, our analysis revealed that the sensitivity and specificity of MK in the diagnosis of HCC ranged from 0.60 to 1.00 (median, 0.87) and from 0.62 to 1.00 (median, 0.84), respectively ([Fig 2A](#pone.0223514.g002){ref-type="fig"}). Neither the visual assessment of the coupled forest plots nor the Spearman correlation coefficient ρ (-0.50, 95% CI -0.85--0.14) supported the threshold effect. For AFP, we incorporated common cutoff values (20, 40 and 200 ng/mL) among the various values addressed by one study for further analysis. The sensitivity and specificity ranged from 0.25 to 0.83 (median, 0.52) and from 0.35 to 1.00 (median, 0.84), respectively ([Fig 2B](#pone.0223514.g002){ref-type="fig"}). No threshold effect was found on the forest plots or with the Spearman ρ (0.38, 95% CI -0.45--0.85).

![Forest plots of (A) MK and (B) AFP.\
High degree of heterogeneities for both sensitivity and specificity estimates were obtained.](pone.0223514.g002){#pone.0223514.g002}

For MK, the pooled sensitivity and specificity were 0.85 (95% CI 0.78--0.91) and 0.83 (95% CI 0.76--0.88), respectively. The sensitivity was statistically superior to that of AFP (p = 0.000), which was only 0.53 (95% CI 0.43--0.64). However, AFP had a slightly better specificity (0.84, 95% CI 0.64--0.94) compared with MK, although the difference was nonsignificant (p = 0.818). We also found a LR+ of 5.05 (95% CI 3.33--7.40) and a LR− of 0.18 (95% CI 0.11--0.28) for MK, and a LR+ of 3.79 (95% CI 1.62--8.25) and a LR− of 0.56 (95% CI 0.46--0.69) for AFP. The Rutter & Gatsonis and Rücker & Schumacher HSROC curves for MK and AFP are shown in [Fig 3](#pone.0223514.g003){ref-type="fig"}. Scattered circles represent individual studies; summary estimates originating from the bivariate model as well as the 95% confidence intervals were also plotted. The data points for MK are clustered in the top left corner, while the data points for AFP are mostly located in the middle left of the plot, indicating that MK is more sensitive than AFP for the diagnosis of HCC. Meanwhile, their similar projection positions on the X-axis indicate that the specificities are comparable. The pooled DORs were 31.74 (95% CI 13.98--72.09) for MK and 6.21 (95% CI 2.62--14.69) for AFP. MK studies had moderate heterogeneity of DOR (Q = 16.00, p = 0.10, I^2^ = 37.52%), and AFP studies had negligible heterogeneity of DOR (Q = 7.85, p = 0.35, I^2^ = 10.83%). The pooled AUCs were 0.91 (95% CI 0.84--0.99) for MK and 0.71 (95% CI 0.53--1.00) for AFP. Evidently, MK had better discriminatory power than AFP to distinguish HCC from non-HCC. The results of the subgroup analyses for MK studies are shown in [Table 2](#pone.0223514.t002){ref-type="table"}. A symmetric funnel plot ([Fig 4](#pone.0223514.g004){ref-type="fig"}) showed no publication bias (p = 0.37) in the included studies according to the method of Deeks *et al*. \[[@pone.0223514.ref023]\].

10.1371/journal.pone.0223514.t002

###### Synopsis of results from subgroup analyses depending on sample type, number of participants, country, control type and cutoff values used for the diagnosis of hepatocellular carcinoma.

![](pone.0223514.t002){#pone.0223514.t002g}

  Characteristics                                     Studies, No.   Participants, No.   Sensitivity, (95% CI)                      Specificity, (95% CI)                      Positive Likelihood Ratio (95% CI)         Negative Likelihood Ratio (95% CI)         Diagnostic Odds Ratio (95% CI)             Area Under the Curve (95% CI)
  --------------------------------------------------- -------------- ------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------
  Sample serum                                        10             1907                0.85 (0.77--0.91)                          0.84 (0.77--0.89)                          5.52 (3.55--8.23)                          0.18 (0.10--0.29)                          35.64 (14.63--86.83)                       0.91 (0.83--1.00)
  Sample blood                                        1              74                  NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}
  Participants ≤100                                   5              359                 0.88 (0.82--0.93)                          0.86 (0.69--0.94)                          6.96 (2.72--15.80)                         0.14 (0.08--0.24)                          58.27 (15.03--225.90)                      0.96 (0.93--1.00)
  Participants \>100                                  6              1622                0.82 (0.73--0.90)                          0.82 (0.70--0.88)                          4.63 (2.69--7.43)                          0.23 (0.12--0.40)                          22.20 (7.77--63.40)                        0.88 (0.78--1.00)
  Country Egypt                                       6              534                 0.91 (0.83--0.96)                          0.85 (0.73--0.92)                          6.56 (3.29--12.20)                         0.11 (0.05--0.21)                          97.73 (22.69--421.04)                      0.98 (0.97--1.00)
  Country China                                       3              997                 NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}
  Country others                                      2              450                 NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}
  Control CLD[^b^](#t002fn003){ref-type="table-fn"}   6              778                 0.85 (0.76--0.90)                          0.79 (0.68--0.87)                          4.17 (2.44--6.80)                          0.20 (0.11--0.34)                          28.79 (7.92--104.65)                       0.91 (0.82--1.00)
  Control normal                                      2              140                 NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}
  Control mixed                                       3              1063                NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}
  Cut off ≤0.5ng/mL                                   4              684                 0.78 (0.61--0.89)                          0.79 (0.66--0.88)                          3.81 (1.96--6.77)                          0.30 (0.14--0.55)                          12.93 (4.21--39.71)                        0.84 (0.75--0.95)
  Cut off \>0.5ng/mL                                  5              1153                0.87 (0.83--0.90)                          0.86 (0.80--0.90)                          6.19 (4.31--8.74)                          0.16 (0.12--0.20)                          57.08 (21.09--154.48)                      0.95 (0.92--0.99)
  Cut off none                                        2              144                 NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}   NA[^a^](#t002fn002){ref-type="table-fn"}

Abbreviations: CLD, chronic liver disease; NA, not available.

^a^Insufficient data for pooling results.

^b^Including cirrhosis, chronic hepatitis B and chronic hepatitis C.

![Diagnostic accuracy comparison between MK and AFP using HSROC curves.](pone.0223514.g003){#pone.0223514.g003}

![Funnel plot over included studies according to Deeks *et al*.](pone.0223514.g004){#pone.0223514.g004}

Discussion {#sec015}
==========

The abnormal expression of MK has been widely investigated in various malignancies \[[@pone.0223514.ref032], [@pone.0223514.ref034]\]. In contrast, MK is rarely detectable in non-malignant blood samples, and the encouraging non-invasive diagnostic potential of MK for tumours is worth in-depth investigation. Jing *et al* concluded that MK has great performance in the diagnosis of malignant diseases such as oesophageal squamous cell carcinoma, paediatric embryonal tumour, colorectal cancer, hepatocellular carcinoma, thyroid cancer, non-small cell lung cancer, mesothelioma and head and neck squamous cell carcinoma. However, tumour heterogeneity confers substantial limitations on the conclusions \[[@pone.0223514.ref035]\]. Here, we found a "good" AUC for MK, compared with a "reasonable" AUC for AFP according to the criterion proposed by Jones *et al*. \[[@pone.0223514.ref036]\]. Likewise, the pooled DOR for MK eclipsed the one for AFP. The overall sensitivity was greater for MK than for AFP (p = 0.000), yet the overall specificity was approximately equal. In summary, MK is an adequate diagnostic biomarker that is generally more sensitive than AFP for the discrimination of HCC patients from normal individual and cirrhosis, CHC, CHB, GIT, BLT and BGID patients.

To the best of our knowledge, this is the first systematic review and meta-analysis evaluating the diagnostic accuracy of MK in HCC individuals. We conducted the current systematic review according to the PRISMA guidelines \[[@pone.0223514.ref012]\] and used a preestablished protocol registered in PROSPERO to guarantee the internal validity of our conclusions. A rigorous search of online databases and grey literature sources without language restriction avoided selection bias stemming from the source of the literature. Two authors (B-H.Z. and B.L.) independently extracted data and assessed the quality of the studies using QUADAS-2 \[[@pone.0223514.ref013]\], a meticulous tool for diagnostic meta-analyses. We used both univariate and bivariate models to synthesize the existing data.

Nine articles including 11 studies were collected and included in the subgroup analyses of MK. We incorporated five covariates: sample type, number of participants, country, control type and cutoff value. As indicated, the pooled sensitivity of the studies with \>100 participants \[[@pone.0223514.ref024], [@pone.0223514.ref026], [@pone.0223514.ref027], [@pone.0223514.ref031], [@pone.0223514.ref032]\] was lower than that of studies with ≤100 participants \[[@pone.0223514.ref025], [@pone.0223514.ref028]--[@pone.0223514.ref030]\]. In addition, the pooled specificity of studies with \>100 participants was lower than that of studies with ≤100 participants. We noticed that the entire population of studies with ≤100 participants was still small, with the maximum sample size of only 75 \[[@pone.0223514.ref028]\]. However, as we know, the small-study effect is a typical mechanism well documented in randomized clinical trial studies, and it seems less marked in diagnostic meta-analyses \[[@pone.0223514.ref037]\]. Furthermore, the pooled sensitivity and specificity of MK in studies with cutoff values \>0.5 ng/mL were manifestly greater than those in studies with cutoff values ≤0.5 ng/mL (0.87 *versus* 0.78 and 0.86 *versus* 0.79, respectively). Similarly, we found greater LR+ (6.19 *versus* 3.81), DOR (57.08 *versus* 12.93) and AUC (0.95 *versus* 0.84) values and lower LR− (0.16 *versus* 0.30) values. These results corroborate that the use of cutoff values \>0.5 ng/mL resulted in the best diagnostic performance. Li *et al* used heparin-ELISA to determine MK expression \[[@pone.0223514.ref027]\]. We noticed that MK can bind to heparin sulfate on the vascular endothelial surface. This combination could undermine the sensitivity and specificity of the use of serum MK for HCC detection. As reported previously, the intravenous administration of heparin could increase the serum MK level in a dose-dependent manner \[[@pone.0223514.ref026]\]. A heparin-ELISA is another type of heparin test that increases the sensitivity of MK, or in other words, lowers the cutoff value (0.07 ng/mL).

Traditional HSROC parametrization (Rutter & Gatsonis method) revealed the conspicuous superiority of MK over AFP with regard to the diagnosis of HCC. It should also be noted that in this meta-analysis, an enrolled study represented the particular population of a single institution and consequently defined flexible optimal cutoff values. The diagnostic efficiency per study could be overestimated, correspondingly increasing the power of the pooled estimates to a certain degree. In this case, an alternative approach, the conservative Rücker & Schumacher method, was employed to compute the HSROC curve, acting as a supplement to account for this tiny flaw. The resulting curves all verified the better diagnostic accuracy of MK compared with AFP. The rate of AFP-negative (\<20 ng/mL) HCC limits the practicability of AFP for HCC surveillance. The secretory ability of hepatic tumours could be dampened by their small size. Even among larger lesions, twenty percent are not correlated with upregulated levels of AFP \[[@pone.0223514.ref031]\]. Five studies agree that the MK level is independent of AFP level \[[@pone.0223514.ref028]--[@pone.0223514.ref030], [@pone.0223514.ref032], [@pone.0223514.ref038]\]. Additionally, four studies reported a high positivity rate for MK in AFP-negative HCC \[[@pone.0223514.ref024], [@pone.0223514.ref028], [@pone.0223514.ref031], [@pone.0223514.ref032]\], suggesting the excellent sensitivity of the combination of MK and AFP. In addition, Vongsuvanh *et al* suggest the capacity of MK to be used for the pre-clinical diagnosis of HCC. In 2000, Ikematsu and colleagues addressed the decreased level of serum MK in 4 out of 5 HCC patients after curative surgery \[[@pone.0223514.ref010]\]. A later study reported that thirty-six HCC patients had experienced a sharp decline in the serum level of MK four weeks after hepatectomy. Meanwhile, the serum levels of MK in patients with documented recurrence (20/36) increased to the preoperative levels \[[@pone.0223514.ref032]\]. However, Hung *et al* concluded that the longitudinal monitoring of serum MK is incapable of detecting HCC recurrence and *de novo* HCC \[[@pone.0223514.ref026]\]. Further well-designed studies with larger sample sizes are needed to settle those disputes.

Limitations should be acknowledged. First, with an exhaustive search procedure, only 9 eligible articles (11 studies) were obtained. Quality assessment uncovered studies with high or unclear risks of bias. This could be explained by their suboptimal study designs. Second, only three studies reported or had sufficient information to calculate the data regarding the diagnostic accuracy of combined MK and AFP; hence, we could not perform a comparative study of the combined and individual diagnostic accuracies. The lack of AFP studies in the included literature and the selection of different cut-off values for AFP may also undermine the stability of our results. Third, the diversity of the control group weakened the accuracy of the specificity values. Specifically, direct-acting antiviral agents (DAA) and nucleotide analogues (NUC) are safe and effective at eradicating HCV and HBV infection, respectively. Therefore, the possible use of DAA or NUC regimens in patients with CHC and CHB in the control group may impede a robust conclusion. Likewise, the aetiology of liver cirrhosis and the trend for the application of lower AFP thresholds (\<20 ng/mL) to monitor HCC recurrence may affect the robustness of the conclusion.

In conclusion, MK has a high diagnostic accuracy for HCC screening. More studies are needed to investigate the differential expression of MK in blood samples from patients with different degrees of liver fibrosis and its value in the diagnosis of cirrhotic and non-cirrhotic liver cancer patients. Whether the combination of MK and AFP provides better performance for HCC detection remains unknown. Further studies with rigorous designs are warranted to complete a full-scale evaluation of combined MK and AFP implementation as a means to accelerate the clinical investigation of individualized screening options.
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AFP

:   α-fetoprotein

AUC

:   area under the curve

BGID

:   benign gastrointestinal disease

BLT

:   benign liver tumor

CBMdisc

:   China Biology Medicine disc

CHB

:   chronic hepatitis B

CHC

:   chronic hepatitis C

DOR

:   diagnostic odds ratio

DSL

:   DerSimonian and Laird

EIA

:   enzyme-linked immunoassay

ELISA

:   enzyme-linked immunosorbent assay

FN

:   false negative

FP

:   false positive

GIT

:   gastrointestinal tumor

HCC

:   hepatocellular carcinoma

HSROC

:   hierarchical summary receiver operating characteristic

I^2^

:   inconsistency index

LR−

:   negative likelihood ratio

LR+

:   positive likelihood ratio

MK

:   midkine

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

QUADAS

:   Quality Assessment of Diagnostic Accuracy Studies

TN

:   true negative

TP

:   true positive

US

:   ultrasound
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Dear Dr. Jia-yin Yang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Although it is of interest, the reviewers have raised a number of points which we believe major modifications are necessary to improve the manuscript, taking into account the reviewers\' remarks. 

==============================

We would appreciate receiving your revised manuscript by Aug 22 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Wisit Cheungpasitporn, MD, FACP

University of Mississippi Medical Center

Twitter: \@wisit661 Email: <wcheungpasitporn@gmail.com> 
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Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Dr. Zhang and colleagues made a comprehensive review of literature on accuracy of midkine for the diagnosis of HCC.

However,

\- Remove "holistic" from introduction section

\- In the result section, authors decribe the control group without HCC as composed by 113 patients with chronic hepatitis C or HBV, without comments on possible DAA or NUC treatment, and by 453 subjects with liver cirrhosis, without specify the etiology of liver disease. In discussion section, this limit should be pointed out and highlighted, as well as the AFP levels used (20-200 ng/mL) for the accuracy comparison are very hight. According to literature, accuracy of AFP for HCC changes according to etiology, and nowadays lower AFP thresholds are under evaluation for increasing HCC surveillance.

\- Add recent EASL HCC guidelines in references section and introduction

\- Only 6 studies evaluated the role of AFP vs MK, and only three AFP+MK: this point of limit numbers of studies on AFP, and moreover with different cut-off on etiology should be stressed in discussion, and also in results section of the abstract. In fact, here there are no data on AFP and MK comparison in result section, but AFP appears in the conclusion statement. Modify results section or change conclusion statement, removing AFP.

Reviewer \#2: This study investigated about the dependability and accuracy of midkine (MK) to diagnose HCC by systematic review and meta- analysis. In this study, 9 articles were incorporated and the authors reported that the sensitivity and specificity of MK for diagnosing HCC were 0.85 and 0.93, respectively. And furthermore, the authors indicate that the best efficient cut-off value of MK level to diagnose HCC was 0.5ng/mL.

Although not entirely novel, this study is potentially interesting to the readers as the authors showed the possibility of MK as a novel diagnostic biomarker of HCC. The study design is well organized and the statistics seem to have been conducted appropriately.

However, I have several points as indicated below need to be addressed in the manuscript by the authors to improve the quality of this article.

Major points

1\. According to the past report by Hung et al, serum MK levels could have potential to be useful to monitor HCC progression. Have you analyzed about the correlation between the HCC stage or prognosis of the patients with HCC and serum MK levels? Of course, I know that this research focused only about the diagnostic usefulness of MK. But if the authors have some informative data about the possibility of MK for prediction of prognosis or monitoring the response to therapy, it would be more useful to include the information about this point.

2\. Is there any difference in MK level according to the liver fibrosis status? Is the cut-off level to diagnose of HCC the same between the cirrhosis and non-cirrhosis patients? Whether the authors have some data or not, it would be useful to mention about this point in result or discussion part.

Minor point

1\. "heparin" in the last line of page 20 is misspelled.

Reviewer \#3: Please also include timeline of the literature search in the method section of the abstract.

Please also include timeline of the literature search in the method section of the Fulltext.

When Pubmed is used for the search, MESH terms are always recommended to be included.

Search terms in PubMed and Embase are different. Please attach syntax used in each database as supplementary.

It will be better to show kappa for the selection and data extraction. Please show the data of kappa of agreement during the systematic searches. How disagreements were solved during the systematic search among two independent reviewers?

Figure1, suggest to use PRISMA 2009 Flow Diagram platform

Please make the data for this review publicly available, possibly through the Open Science Framework (osf.io). Items to include: list of excluded studies, commands for statistical analysis, spreadsheets or data used for the meta-analyses, etc. Making data publicly available will promote the reproducibility of the review and is best practices for systematic reviews and meta-analyses.

Some revision of the English language is needed. There are some parts of the paper where it is quite difficult to make sense of some sentences. English edit will help to improve the quality of the manuscript.

"makes it readily to quantitate in blood samples" is not correct in grammar.

"above fifty percent HCC patients" is not correct

"Studies that with insufficient data" is not correct

"other type" is not correct in grammar.

"10 review and meta-analysis were excluded based upon" is not correct in grammar.

"literatures" is not correct in grammar. It is uncountable noun

"Jing et al concludes that MK demonstrates great performance in the diagnosis of malignant diseases like esophageal squamous cell carcinoma" is not correct. It should be past tense.

"Hung et al concludes that the longitudinal monitoring of serum MK is incapable of detecting HCC recurrence and de novo HCC" is not correct. It should be past tense.

"A recent meta-analysis concludes that US plus AFP may serve as an updated screening strategy

for early HCC." is not correct. It should be past tense.

It is not professional to use "And" at the beginning of sentences in academic writing.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0223514.r002
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I sincerely appreciate your hard work.
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Click here for additional data file.
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Dear Jia-yin Yang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: The reviewer (s) have still raised a number of points which we believe major modifications are necessary to improve the revised manuscript, taking into account the reviewers\' remarks.  Please consider and address each of the comments raised by the reviewers before resubmitting the manuscript. This letter should not be construed as implying acceptance, as a revised version will be subject to re-review.

==============================

We would appreciate receiving your revised manuscript by Oct 17 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Wisit Cheungpasitporn, MD, FACP

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: Some comments this reviewer pinted out were properly addressed. This revewer think the munuscript should be accepted for publication.

Reviewer \#3: The authors claimed they included \"MESH terms in our searchsyntax.\" However, this needs to be mentioned formally in the method section of manuscript. MESH term for Pubmed should be provided in the full manuscript.

The authors claimed \"We attached the syntax used in PubMed and Embase as supplementary.\" However, this is not good enough. Attached file S1 Figure.esp is not professional. This needs to be more formal in the manuscript for as .doc that easy to assess.

The authors claimed they made \"data publicly available through Open Science Framework\"; however, they have not provided the formal like that can access data publicly in the manuscript. Need to include in method section or the first part of result.

The authors claimed they made changes in English edits as \"These mistakes were carefully corrected.\" However, there arevery minor changes in the manuscript and still very difficult to read through in English writing. English language Edit is needed including formal proof.

If the investigators do not take these comments seriously to improve manuscript, I suggest rejection for this submission.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear Dr. Jia-yin Yang,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Wisit Cheungpasitporn, MD, FACP

University of Mississippi Medical Center

Twitter: \@wisit661 Email: <wcheungpasitporn@gmail.com> 
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Additional Editor Comments:

I want to commend the authors on their superb efforts to revise the manuscript according to all reviewers' suggestions. The quality of the manuscript has improved substantially.

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: Authors have fully modified their manuscript. I think this manuscript should be accepted for publication.

Reviewer \#3: All my concerns have been fully elucidated, missing sections and analyses have been completed. Finally, comprehension errors have been corrected. Good work!

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Masanori Atsukawa

Reviewer \#3: No
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Dear Dr. Yang:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Wisit Cheungpasitporn

Academic Editor
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